# CROWN BIOSCIENCE

## Mu**Screen**

Syngeneic and tumor homograft in vivo immunotherapy screening



QUICKFACT

### Rapidly progress your immuno-oncology drug development programs with our highly experienced screening platform.

Choose Mu**Screen** to:

- Screen agents using well-characterized syngeneic and tumor homograft models, with ICI benchmarking, baseline tumor immune profile, and tumor RNAseq data available
- Evaluate single or combination agent strategies
- Efficiently identify responder models
- Uncover mechanism of action and predictive biomarkers
- Benefit from Crown Bioscience covering the cost of the vehicle group for all models
- Maximize the value your MuScreen by choosing either FACS or Mouse I/O RNA-Seq Panel as an optional readout to fast-track *in vivo* preclinical immunotherapy development

#### **Syngeneic Model Panels**


Choose our well-characterized syngeneic model panels, displaying heterogeneous immune phenotypes, for rapid and large scale compound efficacy or PD evaluation.

#### Tumor Homograft Panel

Choose our unique tumor homograft models featuring clinically relevant mutations, for single agent immunotherapy and combination I/O and targeted agent efficacy assessment.

Our unique **MuPrime**<sup>™</sup> tumor homografts are transplants of spontaneous or carcinogen-induced GEMM tumors in immunocompetent syngeneic hosts:

- Carrying disease-relevant oncogenic mutations of human cancers including KRAS, PTEN, and TP53
- Preserving original GEMM tumor histo- and molecular pathology



#### Select the Models and Study Design To Suit Your Program



**Sales** US: +1 858 622 2900 UK: +44 870 166 6234

busdev@crownbio.com www.crownbio.com



Science consultation@crownbio.com

